Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals presented new data at the ESC Congress 2026, showcasing the effectiveness of RNAi-based gene silencing in cardiovascular diseases. The findings reinforce the clinical profile of AMVUTTRA (Vutrisiran) in patients with Transthyretin Amyloidosis (ATTR) across different treatment contexts. This marks a significant advancement in the treatment of ATTR.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data presented at ESC Congress 2026 supports RNAi-based therapy.
  • Demonstrates effectiveness of AMVUTTRA in various ATTR patient groups.
  • Highlights the clinical profile of Alnylam's innovative treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen für RNAi-Therapeutika, hat heute auf dem European Society of Cardiology (ESC) Congress 2026 neue Daten vorgestellt, die die Wirksamkeit des RNAi-basierten Gen-Silencing bei Herz-Kreislauf-Erkrankungen belegen. Die Ergebnisse untermauern das klinische Profil von AMVUTTRA® (Vutrisiran) bei Patientengruppen mit Transthyretin-Amyloidose (ATTR), in verschiedenen Behandlungskontexten und

Frequently Asked Questions

What data did Alnylam present at the ESC Congress 2026?

Alnylam presented new data demonstrating the effectiveness of RNAi-based gene silencing in cardiovascular diseases.

What is AMVUTTRA?

AMVUTTRA (Vutrisiran) is an RNAi-based therapy for patients with Transthyretin Amyloidosis (ATTR).

How does AMVUTTRA benefit ATTR patients?

The data supports AMVUTTRA's efficacy across various ATTR patient groups and treatment contexts.

What is the significance of the ESC Congress 2026 for Alnylam?

The congress provided a platform to showcase Alnylam's advancements in RNAi therapies for cardiovascular conditions.

ShareAdd on Google
Tags: ALNY Viatris Investor Conferences Healthcare Alnylam RNAi ATTR AMVUTTRA ESC Congress
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+25%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →